Answers are grounded in this paper and cite their sources.
Review highlights advances in stem cell therapies for hemorrhagic stroke, suggesting potential for translation from preclinical models to clinical applications.
Hemorrhagic stroke (HS) is a disastrous occurrence with high mortality rates, however, there are no established treatments for this pathology. Given recent advances in stem cell therapies, concerted research efforts have elucidated the therapeutic potential of stem cells in treating HS. In 2020, our group reviewed the use of SCs in regulating the neuroinflammatory reactions which occur after HS.1 This review will build on that work, highlighting more recent advancements in the field of SC treatments for HS. Ultimately, with greater focus in this area of research, innovative SC therapies can be optimized in preclinical studies and soon be transferred to clinical applications for HS therapeutics.
No takes yet. Share an insight, caveat, or question.
Monsour et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: